Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Unspecified Adult Solid Tumor, Protocol Specific|Solid Tumor
Interventions: DRUG: BEZ235 + MEK162
Sponsor: Pfizer